General characteristics at inclusion
| Characteristic | Rituximab infusions | |
| Individually tailored (n=81) | Fixed-schedule (n=81) | |
| Age, means±SD, years | 62±14 | 59±13 |
| Female sex, n (%) | 31 (38.3) | 37 (45.7) |
| Vasculitis type, n (%) | ||
| GPA | 56 (69.1) | 61 (75.3) |
| MPA | 25 (30.9) | 20 (24.7) |
| Disease status, n (%) | ||
| Newly diagnosed | 53 (65.4) | 51 (63.0) |
| Relapsing | 28 (34.6) | 30 (37.0) |
| Induction treatment of last disease flare, n (%) | ||
| Cyclophosphamide | 52 (64.2) | 49 (60.5) |
| Rituximab | 28 (34.6) | 32 (39.5) |
| Methotrexate | 1 (1.2) | 0 (0.0) |
| Prednisone dose (mg); median (IQR) | 10 (10–15)] | 12 (10–17.3) |
| Organ involvement at last flare, n (%) | ||
| Ear, nose and throat | 46 (56.8) | 39 (48.1) |
| Pulmonary | 50 (61.7) | 44 (54.3) |
| Renal | 60 (74.1) | 56 (69.1) |
| GFR, mean±SD, mL/min/1.73 m2 at inclusion | 55.6±27.3 | 58.9±27.0 |
| ANCA-positive at diagnosis, n (%)* | 74/77 (96.1) | 72/79 (91.1) |
| Indirect immunofluorescence | 68/77 (88.3) | 6579 (82.3) |
| ELISA | 64/77 (83.1) | 61/79 (77.2) |
| Anti-PR3 | 38/77 (49.4) | 38/79 (48.1) |
| Anti-MPO | 26/77 (33.8) | 24/79 (30.4) |
| ANCA-positive at inclusion, n (%)† | 45/80 (56.3) | 58/80 (72.5) |
| Indirect immunofluorescence | 40/80 (50) | 54/80 (67.5) |
| ELISA | 28 (35) | 43 (53.7) |
| Anti-PR3 | 18 (22.5) | 21 (26.2) |
| Anti-MPO | 10 (12.5) | 23 (28.7) |
*Data were missing for four individually tailored-infusion and two fixed-schedule-infusion patients.
†Data were missing for one patient in each group.
ANCA, antineutrophil cytoplasm antibodies; GFR, glomerular filtration rate; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase.; PR3, proteinase-3.